Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI
- Conditions
- Microvascular Coronary Artery Disease
- Interventions
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 10
- Registration Number
- NCT03236311
- Locations
- 🇺🇸
Investigational Site Number 8400001, Jacksonville, Florida, United States
🇺🇸Investigational Site Number 8400013, Wellington, Florida, United States
🇩🇰Investigational Site Number 2080001, København Nv, Denmark
Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine
- Conditions
- Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-07-07
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 597
- Registration Number
- NCT03211858
- Locations
- 🇺🇸
Investigational Site Number 8400033, Chattanooga, Tennessee, United States
🇺🇸Investigational Site Number 8400009, Dallas, Texas, United States
🇺🇸Investigational Site Number 8400024, Henderson, Nevada, United States
Sotagliflozin Bioequivalence Study
- First Posted Date
- 2017-07-07
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 76
- Registration Number
- NCT03211195
- Locations
- 🇺🇸
Investigational Site Number 840001, Miami, Florida, United States
A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT03202875
- Locations
- 🇩🇪
Investigational Site 276001, Neuss, Germany
An Observational Study on Teriflunomide-exposed Pregnancies
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 220
- Registration Number
- NCT03198351
- Locations
- 🇺🇸
University of California at San Diego-Site Number:001, San Diego, California, United States
🇨🇦Investigational Site Number :002, Canada, Canada
Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- Conditions
- Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 109
- Registration Number
- NCT03194867
- Locations
- 🇬🇷
Investigational Site Number :3000001, Athens, Greece
🇨🇦Investigational Site Number :1240003, Sherbrooke, Quebec, Canada
🇮🇹Investigational Site Number :3800003, Brescia, Italy
A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors
- Conditions
- Malignant Solid Tumor
- Interventions
- Biological: SAR439459
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 161
- Registration Number
- NCT03192345
- Locations
- 🇧🇪
Investigational Site Number : 0560001, Leuven, Belgium
🇺🇸Tennessee Oncology, PLLC Site Number : 8400006, Nashville, Tennessee, United States
🇺🇸Mary Crowley Cancer Research Center Site Number : 8400003, Dallas, Texas, United States
A Study to Evaluate the Effect of Food on the Pharmacokinetics of Sotagliflozin and to Explore the Relative Bioavailability in Healthy Subjects
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 14
- Registration Number
- NCT03174548
- Locations
- 🇬🇧
Investigational Site Number 826001, Leeds, United Kingdom
Observational Study Describing the Immune Profile Induced By Pertussis Vaccines
- Conditions
- PertussisWhooping Cough
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 90
- Registration Number
- NCT03147898
- Locations
- 🇵🇦
Investigational Site, Panama City, Panama
An Open-label, Non-comparative Study to Document the Tolerability to Ramipril in Patients With at Least One High Risk for Developing a Major Cardiovascular Event
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 179
- Registration Number
- NCT03099213
- Locations
- 🇮🇩
Sanofi Administrative Office, Bali, Indonesia